GridAI Technologies (GRDX) risk factors, FY2024 10-K

Risks Related to Our Business, Financial Position and Capital Requirements

1. 01Our current dependency on external funding for our operations raises a substantial doubt about our ability to continue as a going concern. If we do not continue as a going concern, investors could lose their entire investment
2. 02terminate operations, make reductions in our workforce, discontinue research and development programs, liquidate all or a portion of assets or pursue other strategic alternatives, and/or seek protection under the provisions of the U.S. Bankruptcy Code
3. 03Our level of indebtedness and our ability to make payments on or service our indebtedness could adversely affect our business, financial condition, results of operations, cash flow and liquidity
4. 04We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed and on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product candidate development programs, testing efforts or other operations, including
5. 05additional financing may divert our management from its day-to-day activities, which may adversely affect our ability to develop our product candidates
6. 06Additional offerings in the future may dilute then existing stockholders’ percentage ownership of our Company
7. 07We do not expect to consummate certain previously disclosed proposed transactions
8. 08We are a clinical stage biopharmaceutical company and have a limited operating history upon which to base an investment decision
9. 09We will face intense competition and may not be able to compete successfully
10. 10We may incur substantial product liability or indemnification claims relating to the use of our product candidates
11. 11We use biological materials and may use hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly
12. 12We will need to grow the size of our organization, and we may experience difficulties in managing this growth
13. 13Disruptions in the global economy and supply chains may have a material adverse effect on our business, financial condition and results of operations
14. 14Global conditions, dislocations in the financial markets, any negative financial impacts affecting United States as a result of tax reform or changes to existing trade agreements or tax conventions, may adversely impact our business
15. 15Geopolitical risks associated with Russia’s invasion of Ukraine and Israel’s war with Hamas could result in increased market volatility and uncertainty, which could negatively impact our business, financial condition, and results of operations
16. 16Significant disruptions of information technology systems or breaches of data security could materially adversely affect our business, results of operations and financial condition
17. 17Requirements associated with being a public company will increase our costs significantly and will divert significant company resources and management attention

Risks Related to Clinical Development, Regulatory Approval and Commercialization

1. 18Our product candidates are at an early stage of development and may not be successfully developed or commercialized
2. 19Any product candidates we advance into and through clinical development are subject to extensive regulation, which can be costly and time consuming, cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates
3. 20If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected
4. 21Because the results of preclinical studies and early clinical trials are not necessarily predictive of future results, any product candidate we advance into clinical trials may not have favorable results in later clinical trials, if any, or receive regulatory approval
5. 22Any product candidate we advance into and through clinical trials may cause unacceptable adverse events or have other properties that may delay or prevent their regulatory approval or commercialization or limit their commercial potential
6. 23Delays in the commencement or completion of our clinical trials could result in increased costs and delay our ability to pursue regulatory approval and commercialization of our product candidates
7. 24We may be required to suspend, repeat or terminate our clinical trials if they are not conducted in accordance with regulatory requirements, the results are negative or inconclusive or the trials are not well designed
8. 25Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of the approved labeling, or result in significant negative consequences following marketing approval, if any
9. 26We are a clinical-stage biopharmaceutical company and have yet to begin to generate revenue from Adrulipase. Our product candidate is in an early stage of clinical development, and, if we obtain marketing approval for any of products in the future, which we anticipate would not occur for several years, if at all
10. 27We have no commercial infrastructure. In order to commercialize products that are approved for marketing, we must either establish our own sales and marketing infrastructure or collaborate with third parties that have such commercial infrastructure
11. 28We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements
12. 29We rely on third parties to manufacture our product candidates
13. 30We intend to rely on market exclusivity periods that may not be or remain available to us
14. 31If we fail to attract and retain key management and clinical development personnel, we may be unable to successfully develop or commercialize our product candidates
15. 32Healthcare reform and restrictions on reimbursements may limit our financial returns
16. 33Changes in healthcare law and implementing regulations, including government restrictions on pricing and reimbursement, as well as healthcare policy and other healthcare payor cost-containment initiatives, may negatively impact our ability to generate revenues

Risks Related to our Intellectual Property

1. 34Our success will depend upon intellectual property, proprietary technologies and regulatory market exclusivity periods, and we may be unable to protect our intellectual property
2. 35If we or our partners are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business
3. 36Our ability to compete may decline if we do not adequately protect our proprietary rights
4. 37If we breach our license or other intellectual property-related agreements for our product candidates or otherwise experience disruptions to our business relationships with our licensor, we could lose the ability to continue the development and commercialization of our product candidates

Risks Related to our Securities

1. 38Our failure to maintain compliance with Nasdaq’s continued listing requirements could result in the delisting of our Common Stock
2. 39Our Common Stock is currently listed for trading on The Nasdaq Stock Market LLC. We must satisfy the continued listing requirements of Nasdaq, to maintain the listing of our Common Stock on The Nasdaq Stock Market LLC
3. 40result of a deliberate intent to avoid compliance, and as such, the Staff does not believe that delisting our securities is an appropriate sanction and that it is appropriate to close these matters by issuing the Letter of Reprimand
4. 41The limited public market for our securities may adversely affect an investor’s ability to liquidate an investment in us
5. 42The market price of our Common Stock may be volatile which could subject us to securities class action litigation and prevent you from being able to sell your shares at or above the offering price
6. 43We have never paid and do not intend to pay cash dividends on our Common Stock. As a result, capital appreciation, if any, will be your sole source of gain
7. 44Provisions in our Charter, our amended and restated by-laws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our Common Stock
8. 45If securities or industry analysts do not publish research or reports about our business, if they adversely change their recommendations regarding our shares or if our results of operations do not meet their expectations, our share price and trading volume could decline
9. 46Our Board has the authority to fix and determine the relative rights and preferences of preferred stock. Our Board also has the authority to issue preferred stock without further stockholder approval